



SYNTHESIS AND CHARACTERIZATION OF SOME NEW THIAZOLIDINONES CONTAINING COUMARIN MOIETY AND THEIR ANTIMICROBIAL STUDY

S. P. Kushwaha* and Dr. Sokindra Kumar

Department of Pharmaceutical Chemistry, R.V. Northland Institute G. B. Nagar,
Greater Noida, Dist- Dadri (Uttar Pradesh), India- 203207.

Article Received on
20 Feb. 2018,

Revised on 14 Mar. 2018,
Accepted on 03 Apr. 2018

DOI: 10.20959/wjpps20185-11419

*Corresponding Author

S. P. Kushwaha

Department of
Pharmaceutical Chemistry,
R.V. Northland Institute G.
B. Nagar, Greater Noida,
Dist- Dadri (Uttar Pradesh),
India- 203207.

ABSTRACT

A novel thiazolidinones series have been synthesized by reaction of different Schiff bases of coumarin with iodoacetic acid. The reaction of 4-hydroxy coumarin with phosphorus pentachloride (PCl₅) yielded 4-chloro coumarin **2** and 4-chloro-3, 4', 3', 4''-tercoumarin **2a**. Compound **2** was reacted with p-toluenediamine sulfate to give 4-[(4-aminophenyl)amino]-2H-chromen-2-one. Various Schiff bases of coumarin were synthesized by condensation of 4-[(4-aminophenyl)amino]-2H- chromen-2-one with different aldehydes. The structures of the newly synthesized compound were confirmed by IR, ¹H NMR, ¹³C NMR and C, H, N analysis. The thiazolidinone derivatives were evaluated for their anti bacterial and antifungal activity by broth dilution method.

KEYWORDS: Coumarin, Schiff bases, thiazolidinone, antibacterial, antifungal.

INTRODUCTION

4-Thiazolidinones and their derivatives are an important class of compounds in organic and medicinal chemistry. The 4-thiazolidinone ring system is a core structure in various synthetic pharmaceutical agents, which display a broad spectrum of biological activities such as, anti-tubercular^[1], anti bacterial^[2], anti-HIV^[3], NSAIDS^[4], anti-mycobacterial^[5], anti convulsant^[6], anti-histaminic^[7], anti-cancer^[8], anti-protozoal^[9] and analgesic.^[10] 4-Thiazolidinones are derivatives of thiazolidine with carbonyl group at the 4th position and formed by the attack of sulphur nucleophile on imine carbon (a functional group or chemical compound containing a

carbon nitrogen double bond) followed by intramolecular cyclization with elimination of water.

Coumarin and its derivatives represent one of the most active classes of compound possessing a wide spectrum of biological activity.^[11-13] Novobiocin and chlorobiocin are established antimicrobials containing a coumarin skeleton.^[14] Many of these compounds have proved to be active as, antibacterial^[15-17], antifungal^[18], anti-inflammatory^[19], anticoagulant^[20], anti-HIV^[21] and anti-tumor^[22]; In addition, these compounds are used as additives to food and cosmetics.^[23] Coumarin derivatives are commonly used as optical whiteners, luminescence.

Similarly coumarin derivatives have been of great interest because of their role in natural and synthetic organic chemistry. Many products which contain a coumarin subunit exhibit biological activity such as molluscicides, 14 anthelmintic, hypnotic, insecticidal¹⁵ activity and some are serving as anticoagulant agents 16 and fluorescent brighteners. So coumarins containing a Schiff base are expected to have enhanced antitumor and other biological activities. The biological activity associated with the hydrazone compounds attributed to the presence of the active pharmacophore (-CONH-N=C-). Hence many hydrazone compounds containing this active moiety showed good anticancer bioactivities according to the literature. 17dyes^[24], active media for lasers^[25] and solar collector.^[26] Various analogues of 4-substituted coumarin such as 4-chlorocoumarins exhibit antimicrobial activity. From the above line of reasoning we directed our work towards synthesis of various coumarin derivatives of biological interest using 4-chloro coumarin as a key starting material.

The aim of the present work was to synthesized new thiazolidinone derivatives containing coumarin moiety in order to find new biologically active compound. Thus, synthesis of novel 4-Thiazolidinones derivatives has been achieved.

MATERIALS AND METHODS

Experimental: All the chemicals used in the synthesis were of analytical grade. The melting points were determined in open capillary on Veego (Model: VMP-D) electronic apparatus. The IR spectra of synthesized compounds were recorded on Shimadzu 8400-S FT-IR spectrophotometer using potassium bromide. To monitor the reactions, as well as, to establish the identity and purity of reactants and products, thin layer chromatography and high performance thin layer chromatography was performed on microscopic glass slides (2x7.5

cm) coated with silica gel-G, using toluene-acetone, benzene-ether and chloroform-methanol, as the solvent systems and spots were visualized under UV radiation. Nuclear magnetic resonance spectra were recorded on Varian 400 MHz model spectrometer using DMSO as a solvent and TMS as internal reference (Chemical shifts in δ ppm). All new compounds were analyzed for C, H, and N and the results are in acceptable range.

2.1-Material: 4-Hydroxy coumarin, triethyl amine (TEA), PCl_5 (Phosphorus pentachloride), para-toluene diamine sulfate (PTDs), aldehydes, iodoacetic acid.

2.2-Synthesis of 4-chloro coumarin (2)

4-Hydroxycoumarin **1** (30 g, 0.185 mol) and 70 mL PCl_5 were refluxed for 1h, cooled, and slowly poured into crushed ice (700 g) with vigorous stirring. The solid was collected by filtration and washed successively with ice-water. Heterogenous or extractive or Azeotropic distillation with n-hexane, hot filtration of the by-product (15 g, 17%), followed by evaporation of solvent and crystallization yielded (21.9 g, 65 %) of 4-chloro coumarin with m.p. 87-89 °C^[27] IR (KBr, cm^{-1}) 1664.62(C=O of coumarin), 773.48 (Ar-C-Cl);¹H-NMR (400 MHz, DMSO- d_6) δ 7.30-7.91 (m, 3H, Ar-H), 7.93 (d, 1H, H at C-5 of coumarin), 5.75 (s, 1H, H at C-3 of coumarin); ¹³C NMR 117.22, 118.14, 124.87, 125.84, 130.18, 146.04, 149.04, 149.22, 161.23. Anal. Calcd. For $\text{C}_9\text{H}_5\text{ClO}_2$: C, 59.86; H, 2.79. Found C, 59.88; H, 2.76.

4-chloro-3, 4', 3', 4''-tercoumarin (by-product) (**2a**): crystallization from acetic acid gave yellowish crystals, m.p. 322-327 °C. IR (KBr, cm^{-1}) 769.62(C-Cl), 1718 (C=O), 1593-1625 (Aromatic -CH str.), 3039-3080 (C=C), 1187 (C-O str.); ¹H-NMR (400 MHz, DMSO- d_6) δ 7.46-7.92 (m, 9H, Ar-H), 7.27 (s, 1H, 3'-H); ¹³C NMR 114.56, 117.60, 118.01, 118.30, 118.83, 118.96, 120.05, 123.40, 124.83, 125.55, 126.00, 126.10, 126.52, 126.69, 132.59, 133.32, 136.13, 149.96, 151.12, 151.95, 156.75, 157.00, 161.80, 163.25. Anal. Calcd. For $\text{C}_{27}\text{H}_{13}\text{ClO}_6$: C, 69.16; H, 2.79. Found C, 69.20; H, 2.75.

2.3-Synthesis of 4-[(4-Aminophenyl)amino]-2H-chromen-2-one (3)

To a boiling solution of the 4-chloro coumarin (10 g, 0.05mol) and little amount of Triethyl amine in ethanol (30 mL) was added to a boiling solution of p-toluenediamine sulfate (6.09 g, 0.05mol) in ethanol (30 mL). The mixture was refluxed for 1h and left at room temperature for 0 4-5 h. The precipitate was separated and recrystallized from DMF. Yield:78 %; m.p. 265-273 C; IR (KBr, cm^{-1}) 3341.78 (NH str. for 20), 3290.67, (NH for 10), 1664.62(C=O of

coumarin); ¹H-NMR (400 MHz, DMSO- d₆) δ 6.53-7.26 (m, 7H, Ar-H), 3.31(s, 2H, NH₂), 3.76 (s, 1H, C-NH), 7.93 (d, 1H, H at C-5 of coumarin), 5.75 (s, 1H, H at C-3 of coumarin); ¹³C NMR 88.22, 116.51, 118.91, 121.80, 123.59, 124.25, 125.79, 131.84, 132.55, 145.13, 149.08, 155.32, 161.98. Anal. Calcd. For C₁₅H₁₂N₂O₂: C, 71.42; H, 4.79; N, 11.10. Found C, 71.40; H, 4.82; N, 11.06.

2.4-General procedure for the synthesis of Schiff bases (4a-i)

To a solution of compound **3** (1.36g; 0.01mol) in absolute ethanol (50 mL), containing a catalytic amount of piperidine, equimolecular amount of the appropriate aldehydes (for e.g. benzaldehyde) was added. The reaction mixture was heated under reflux for 8-10 h. It was then cooled at room temperature, poured into crushed ice, filtered, washed, dried and recrystallized from DMF to yield 4-[(4-[(E)-phenylmethylidene]amino}phenyl)amino]-2H-chromen-2-one. Other Schiff bases were obtained in similar manner.

2.5-General procedure for the synthesis of thiazolidinone (5a-i)

A mixture of compound **4a** and iodoacetic acid in dry benzene (80) mL was refluxed for 6h. Water formed during the reaction was removed extractively or azeotropically by Dean-Stark apparatus. Progress of the reaction the reaction was checked by TLC using benzene-ether as eluant. After the completion of reaction benzene was removed by distillation to give solid, which was dissolved in methanol (70 mL). This solution was warmed and treated with sodium bicarbonate solution to remove unreacted acid. The solid obtained was filtered, washed with ether and purified by crystallization from methanol to give **5a**. Similarly, other compounds (**5b-5i**) have been synthesized.

2.6-Characterization of synthesized compounds (5a-i)

3-[4-(2-oxo-2H-chromen-4-ylamino)-phenyl]-2-phenyl-thiazolidin-4-one (**5a**) Yield: 70%; m.p. 240-245°C; IR (KBr, cm⁻¹): 3296.46 (N-H str.), 1724.42 (C=O of β-lactum), 1664.62 (C=O of coumarin); ¹H -NMR (400 MHz, DMSO- d₆) δ 6.40-7.68 (m, 13H, Ar-H); 3.76 (s, 1H, C-NH); 8.19 (d, 1H, H at C-5 of coumarin), 5.80 (s, 1H, H at C-3 of coumarin), 4.10 (s, 2H, CH₂); ¹³C NMR 38.25, 69.70, 89.19, 117.49, 119.91, 122.48, 123.70, 124.10, 124.40, 125.70, 130.18, 132.60, 136.38, 140.64, 141.75, 154.70, 160.44, 172.10 Anal. Calcd. for = C₂₄H₁₈N₂O₃S; C, 69.55; H, 4.38; N, 6.76. Found: C, 69.52; H, 3.40; N, 6.76. 2-(4-Nitrophenyl)-3-[4-(2-oxo-2H-chromen-4-ylamino)-phenyl]-thiazolidin-4-one (**5b**) Yield: 70%; m.p. 245-251°C; IR (KBr, cm⁻¹): 3296.46 (N-H str.), 1728.28 (C=O of β-lactum), 1664.62 (C=O of coumarin), 1548.89 cm⁻¹(N=O str.); ¹H -NMR (400 MHz, DMSO- d₆) δ 6.40-7.70

(m,12H,Ar-H); 3.76 (s,1H,C-NH); 8.19 (d, 1H, H at C-5 of coumarin), 5.75 (s, 1H, H at C-3 of coumarin),4.10 (s,2H,CH₂); ¹³C NMR 38.25, 69.70, 89.10, 117.49, 119.91, 122.48, 123.10, 123.75, 124.10, 124.40, 125.70, 132.60, 136.38, 140.64, 145.70, 148.35, 149.88, 154.70, 160.44, 172.10. Anal. Calcd. For = C₂₄H₁₇N₃O₅S: C, 62.74; H, 3.73; N, 9.15. Found: C, 62.70; H, 3.74; N, 9.14.

2-(3-Nitro-phenyl)-3-[4-(2-oxo-2H-chromen-4-ylamino)-phenyl]-thiazolidin-4-one

(5c)Yield: 72%; m.p. 259--2650C; IR (KBr,cm⁻¹): 3296.46 (N-H str.), 1720.70 (C=O of β-lactum), 1664.62 (C=O of coumarin, 1537.32 cm⁻¹(N=O str.); ¹H -NMR (400 MHz, DMSO-d₆) δ 6.40-7.70 (m,12H,Ar-H); 3.76 (s,1H,C-NH); 8.19(d, 1H, H at C-5 of coumarin), 5.75 (s, 1H, H at C-3 of coumarin), 4.10 (s,2H,CH₂);¹³C NMR 38.25, 69,70, 89.10, 117.49, 117.49, 118.10, 119.05, 119.91,122.48, 123.10, 124.15, 124.40, 128.60, 132.60, 136.38, 140.64, 145.70, 148.35, 149.88, 154.70, 160.44, 172.10. Anal. Calcd. For = C₂₄H₁₇N₃O₅S: C, 62.74; H, 3.73; N, 9.15. Found: C, 62.72; H, 3.74; N, 9.14. 2-(3, 4-Dimethoxy-phenyl)-3-[4-(2-oxo-2H-chromen-4-ylamino)-phenyl]-thiazolidin-4-one **(5d)**.

Yield: 68%; m.p. 270-2740C; IR (KBr,cm⁻¹): 3296.46 (N-H str.), 1749.49 (C=O of β-lactum), 1664.62 (C=O of coumarin), 1292.35 cm⁻¹(Ar-OCH₃); ¹H -NMR (400 MHz, DMSO- d₆) δ 6.40-7.70 (m,11H,Ar-H); 3.76 (s,1H,C-NH); 8.19 (d, 1H, H at C-5 of coumarin), 5.75 (s, 1H, H at C-3 of coumarin), 3.38 (S,3H,-OCH₃), 4.10 (s,2H,CH₂); ¹³C NMR 38.25, 59.80, 69.70, 110.80, 115.65, 117.49, 118.05, 118.90, 122.48, 123.10, 124.10, 124.40, 132.60, 134.70, 136.38, 140.64, 148.90, 149.85, 151.70, 154.70, 160.44, 172.10. Anal. Calcd. For= C₂₆H₂₂N₂O₅S: C, 65.81; H, 4.67; N, 5.90 Found: C, 65.81; H, 4.68; N, 5.88.

2-(4-Chloro-phenyl)-3-[4-(2-oxo-2H-chromen-4-ylamino)-phenyl]-thiazolidin-4-one **(5e)**

Yield: 80%; m.p. 262-2680C; IR (KBR,cm⁻¹): 3296.46 (N-H str.), 1732.20 (C=O of β-lactum), 1664.62 (C=O of coumarin), 758.05 cm⁻¹(Ar- C-Cl); ¹H -NMR (400 MHz, DMSO-d₆) δ 6.40-7.66 (m,12H,Ar-H); 3.76 (s,1H,C-NH); 8.19 (d, 1H, H at C-5 of coumarin), 5.75 (s, 1H, H at C-3 of coumarin), 4.10 (s,2H,CH₂); ¹³C NMR 38.25, 69.70, 117.49, 118.10, 122.48, 123.10, 124.05, 124.10, 128.44, 128.80, 130.45, 132.60, 134.70, 140.64, 140.80, 149.88, 154.70, 160.44,172.10. Anal. Calcd. For C₂₄H₁₇ClN₂O₃S: C, 64.21; H, 3.82; N, 6.24. Found: C, 64.22; H, 3.82; N, 6.21.


3-[4-(2-Oxo-2H-chromen-4-ylamino)-phenyl]-2-p-tolyl-thiazolidin-4-one (**5f**) Yield: 76%; m.p. 281-2840C; IR (KBR,cm-1): 3296.46 (N-H str.), 1747.57 (C=O of β -lactum), 1664.62 (C=O of coumarin), 1469.81 cm-1(Ar-CH₃); ¹H -NMR (400 MHz, DMSO- d₆) δ 6.40-7.72 (m,12H,Ar-H); 3.76 (s,1H,C-NH); 8.19 (d, 1H, H at C-5 of coumarin), 5.75 (s, 1H, H at C-3 of coumarin), 2.16 (S,3H,CH₃), 4.10 (s,2H,CH₂); ¹³C NMR 23.50, 38.25, 69.70, 89.10, 117.49, 118.10, 122.48, 123.10, 124.05,124.40, 128.44, 128.80, 130.45, 132.60, 134.70, 140.64, 140.80, 149.88, 154.70, 160.44, 172.10. Anal. Calcd. For = C₂₅H₂₀N₂O₃S: C, 70.07; H, 4.70; N, 6.54. Found: C, 70.09; H, 4.69; N, 6.54.

2-{4-oxo-3-[4-(2-oxo-2H-chromen-4-ylamino-phenyl)-thiazolidin-2-yl]-benzaldehyde (**5g**) Yield: 75%; m.p. 281-2860C; IR (KBr,cm-1): 3296.46 (N-H str.), 1716.47 (C=O of β -lactum), 1664.62 (C=O of coumarin), 2933.83 (Ar-CHO Str); ¹H -NMR (400 MHz, DMSO-d₆) δ 6.40-7.70 (m,12H,Ar-H), 3.76 (s,1H,C-NH), 8.19 (d, 1H, H at C-5 of coumarin), 5.75 (s, 1H, H at C-3 of coumarin), 10.22 (s,1H,CHO), 4.10 (s,2H,CH₂); ¹³C NMR 38.25, 69.70, 89.10, 117.49, 119.91, 122.48, 123.70, 124.10, 124.40, 125.05, 125.30, 127.50, 132.60, 134.70, 135.10, 136.05, 140.64, 149.88, 154.70, 160.44, 172.10, 191.88 Anal. Calcd. For = C₂₅H₁₈N₂O₄S: C, 67.86; H, 4.10; N, 6.33. Found: C, 67.86; H, 4.08; N, 6.30.

2-Naphthalen-1-yl-3-[4-(2-oxo-2H-chromen-4-ylamino)-phenyl]- thiazolidin-4-one (**5h**) Yield: 77%; m.p. 291-2960C; IR (KBr,cm-1): 3296.46 (N-H str.), 1735.63 (C=O of β -lactum), 1664.62 (C=O of coumarin), ¹H-NMR (400 MHz, DMSO- d₆) δ 6.40-7.90 (m,15H,Ar-H), 3.76 (s,1H,C-NH), 8.19 (d, 1H, H at C-5 of coumarin), 5.75 (s, 1H, H at C-3 of coumarin), 4.10 (s,2H,CH₂); ¹³C NMR 38.25, 65.10, 89.10, 117.49, 122.48, 123.70, 124.10, 124.40, 127.20, 127.80, 128.50, 130.05, 130.31, 131.25, 132.60, 135.10, 138.40, 149.88, 154.70, 160.44, 172.10 Anal. Calcd. For= C₂₈H₂₀N₂O₃S: C, 72.39; H, 4.34; N, 6.03. Found: C, 72.37; H, 4.36; N, 6.02.

2-(2-Chloro-quinoline-3-yl)-3{4-(2-oxo-2H-chromen-4-ylamino)-phenyl}-thiazolidin-4-one (**5i**) Yield: 72%; m.p. 279-2830C; IR (KBr,cm-1): 3296.46 (N-H str.), 1745.20 (C=O of β -lactum), 1664.62 (C=O of coumarin), 823.40 (Cl of quinoline), ¹H-NMR (400 MHz, DMSO- d₆) δ 6.40-8.09 (m,13H,Ar-H), 3.76 (s,1H,C-NH), 8.19 (d, 1H, H at C-5 of coumarin), 5.75 (s, 1H, H at C-3 of coumarin), 4.10 (s,2H,CH₂); ¹³C NMR 36.15, 56.10, 86.10, 116.50, 118.23, 122.62, 124.70, 124.25, 126.30, 128.60, 128.80, 130.02, 132.55, 133.49, 135.30, 136.60, 139.55, 147.70, 150.40,152.75, 160.85, 173.59. Anal. Calcd. For= C₂₇H₁₈ClN₃O₃S: C, 64.86; H, 3.63; N, 8.40. Found: C, 64.88; H, 3.64; N, 8.40.

Figure 1:



Scheme: Synthesis of thiazolidinone derivatives

	Ar
A	Phenyl
B	4-Nitro phenyl
C	3-Nitro phenyl
D	3,4-dimethoxy phenyl
E	4-chloro phenyl
F	4-methyl phenyl
G	Phenyl-2-Carboxaldehyde
H	Naphthyl
I	2-chloro quinonyl

2.7 Antimicrobial activity

All the synthesized compounds were tested for their antibacterial and antifungal activity (MIC-minimum inhibition concentration) *in vitro* by broth dilution method with two gram positive bacteria *S. aureus* and *B. subtilis* and gram negative bacteria *E. coli*, *P. aeruginosa*, and fungi species like *C. albicans*, *A. niger* organisms taking ciprofloxacin, ampicillin, chloramphenicol, norfloxacin, flucanazole, griseofulvin, and Nystatin. Muller Hinton broth was used as nutrient medium to grow and dilute the drug suspension for test. DMSO was used as a diluent which not effected the growth of microbes.

In order to probe the biological profile of the thiazolidinone series, we conducted a number of additional microbiological assays.

We selected compounds 4-chloro-3,4,3',4''-tercaumarin since it had relatively good activity in solid assays with an MIC of 6.6 1M. The most active compound 4-chloro-3,4,3',4''-tercaumarin was tested for bactericidal activity in aerobic, replicating culture and under non-replicating conditions generated by nutrient starvation.

Interestingly the active compound (4-chloro-3,4,3',4''-tercaumarin) which is a derivative of thiazolidinone was bactericidal against *M. Tuberculosis* under different conditions and in aerobic culture a loss of 4.




Figure 2. days




Figure 3. days

Figure 2. 4-chloro-3,4,3',4'' tercaumarin inhibit growth of *M. tuberculosis* under iron-excess conditions. Cells were inoculated to a starting OD₅₉₀ of 0.04 into growth medium containing no compound 14 (circles), 28 mM compound 14 (triangles) and 56 mM compound 14 (squares). Growth was monitored in the presence (solid symbols) and absence (open symbols) of 40 mg/mL hemin supplement.

Figure 3. 4-chloro-3,4,3',4'' tercaumarin inhibition of *M. tuberculosis* is not dependent on carbon source. Cells were inoculated to a starting OD₅₉₀ of 0.04 into growth medium containing no compound 14 (circles), 14 mM compound 14 (triangles) and 28 mM compound 14 (squares). Growth in medium containing palmitic acid (solid symbols) was compared to that containing OADC (open symbols) supplement.

RESULTS AND DISCUSSION

All the reactions were carried out under conventional methods. 4-[(4-Aminophenyl)amino]-2H-chromen-2-one **3** was a key intermediate that required to prepare the target product. 4-Chloro coumarin **2** was prepared from 4-hydroxy coumarin **1**. But the selectivity of the reaction of **1** with POCl₅ was low, because a considerable amount of 4-chloro-3, 4', 3', 4'-tercoumarin was formed as a byproduct. In this method n-hexane was used to improve the yield of 4-chloro coumarin and significantly decreased yield of the by product. The key intermediate 4-[(4-aminophenyl)amino]-2H-chromen-2-one **3** was easily prepared from 4-chloro coumarin using little amount of triethyl amine. The IR spectra of compound **3** revealed a strong band at 3290.67 cm⁻¹ confirming the presence of 20 –NH group and band at 3341.78 cm⁻¹ indicating the presence of 10-NH₂ group. The IR spectrum of compound **3** showed a band in the region of 1664.62 cm⁻¹ which is the characteristic for C=O of coumarin. The ¹H NMR data of compound **3** revealed signal between 6.53-7.26 δ ppm for aromatic protons. The IR spectra of compound **4b** revealed a characteristic band at 3296.46 cm⁻¹ confirming the presence of 20 –NH group and there was no any band at 3341 cm⁻¹ confirming that –NH₂ group of compound **3** completely reacted with –CHO group of aldehyde to form Schiff base. Stretching vibration for C=N of Schiff base present at around 1473-1602 cm⁻¹. The ¹H NMR data of compounds revealed signal between 6.55-7.52 δ ppm for aromatic protons. All the Schiff bases reacted with Thioglycolic acid to afford thiazolidinone derivatives. IR spectrum of the compound **5b** showed a characteristic band at 1728.28 cm⁻¹ confirming the presence of C=O group thiazolidinone. The ¹H NMR data of compound **5b** revealed signal between 6.40-7.70 δ ppm for aromatic protons and doublet at 4.10 δ ppm for –CH₂ of thiazolidinones.

All the newly synthesized compounds were screened for their antimicrobial activity. From the result in table 1 Schiff base **4e** showed excellent activity when compared with ampicillin and chloramphenicol; while **5b**, **5e**, **5f** and **5i** demonstrated good activity against E.coli and **5e**, **5i** significant activity against P.aeruginosa; while **4c**, **5b**, **5e**, **5i** showed good activity against S.aureus and **5e** and **5i** demonstrated significant activity against B.subtilis when compared with standard drug ampicillin.

5h, **5i** demonstrated good activity against C. albicans when compared with Griseofulvin. All remaining compounds demonstrated good to moderate activity against remaining fungal specie (A. niger).

Table 1 Antimicrobial study (MIC $\mu\text{g/mL}$) of synthesized compound 4a-5i*Minimum inhibitory concentration*

Comp. no.	Ar	Gram negative		Gram positive		Fungal species	
		<i>E. coli</i>	<i>P. aeruginosa</i>	<i>S. aureus</i>	<i>B. subtilis</i>	<i>C. albicans</i>	<i>A. niger</i>
4a	Phenyl	500	1000	500	1000	500	1000
4b	4-Nitro phenyl	200	200	500	1000	800	1000
4c	3-Nitro phenyl	500	200	100	200	500	1000
4d	3,4-dimethoxy phenyl	200	500	1000	200	100	500
4e	4-chloro phenyl	50	100	200	100	500	>1000
4f	4-methyl phenyl	100	200	1000	500	200	500
4g	Phenyl-2-carboxaldehyde	500	1000	800	100	500	1000
4h	Naphthyl	500	250	800	100	400	1000
4i	2-chloro quinonyl	250	400	500	100	400	>1000
5a	Phenyl	400	400	250	400	800	1000
5b	4-Nitro phenyl	200	250	200	250	250	800
5c	3-Nitro phenyl	400	500	500	250	1000	1000
5d	3,4-dimethoxy phenyl	250	400	800	400	200	500
5e	4-chloro phenyl	50	100	200	100	250	400
5f	4-methyl phenyl	50	100	250	250	200	800
5g	Phenyl-2-carboxaldehyde	250	500	500	200	200	800
5h	Naphthyl	400	500	400	250	250	400
5i	2-chloro quinonyl	100	100	100	50	200	500
Ampicilli		100	100	250	100	-	-
Ciprofloxacin		25	25	50	50	-	-
Chloramphenicol		50	50	50	50	-	-
Norfloxacin		10	10	10	10	-	-
Griseofulvin						500	100
Nystatin						100	100
Flucanazole						10	10

From the MIC results of fungal activity, Schiff base **4d** was found equipotent to Nystatin; while **4a**, **4c**, **4e**, **4f**, **4g**, **4h**, **4i** demonstrated significant activity. The thiazolidinones **5b**, **5d**, **5e**, **5f**, **5g**.

CONCLUSION

A series of thiazolidinones, coumarin based compounds were successfully synthesized and tested for their antimicrobial activity (In-vitro). Overall conclusion made for synthesized compounds are that most of the compounds were more active against *E. coli*, *S. aureus* and *B. subtilis*. Some of the compounds were found equipotent or strong to ampicillin and found less active than other standard drugs. Most of the compounds demonstrated antifungal activity for *C. albicans* similar to that of Griseofulvin, found less active than other fungal specie (*A. niger*).

REFERENCES

1. M Naeem; MN Chaudhary; FH Baloch; R Amjad, *J.chem. soc. pak*, **2009**; 31(40): 633-637.
2. MC Sharma; NK Shahu; DV Kohli; SC Chaturvedi; S Sharma, *Digest journal of Nanomaterials and Bio structures*, **2009**; 4(1): 223-232.
3. RB Patel; PS Desai; KR Desai; KH Chikhaliya, *Indian journal of chemistry*, **2006**; 45B: 773.
4. Z Turgut; C Yolacan; F Aydogan; E Bagdatli; N Ocal, *Molecules*, **2007**; 12: 2151-2159.
5. S Bouzroua; Y Bentarzi; R Kaoua; BN Kolli; SP Martini; E Dunach, *Org. Commun*, **2010**; 3(1): 8-14.
6. KM Mistry; KR Desai, *E-journal of chemistry*, **2004**; 1(4): 189-193.
7. N Shah; PC Pant; PC Joshi, *Asian J. chem.*, **1993**; 95: 83.
8. N Ramalakshmi; L Aruloly; S Arunkumar; K Ilango; A Puratchikody, *Malaysian journal of science*, **2009**; 28(2): 197-203.
9. NB Patel; VN Patel, *Iranian journal of pharmaceutical research*, **2007**; 6(4): 251-258.
10. MG Vigorita; R Ottana; F Monforte; R Maccari; Trovato; MT Monforte, MF Taviang, *Biorg. Med.Chem.Lett*, **2001**; 11: 2791-2794.
11. H Zuo; G Jose; Z Boli; B Hyunmoon; D Soo shin; M Ghate, *Arkivoc*, **2008**; 2: 183-189.
12. S Lee; K Sivakumar; W Seobshin; F Xie; Q Wang, *Biorganic & Medicinal Chemistry Letters*, **2006**; 16: 4596-4599.
13. K Moghadam; M Mohseni, *Montash Chem*, **2004**; 135: 817-821.
14. SV Dekic; VS Dekic; BR Dekic; MS Dekic, *Chem. Pap.*, **2007**; 61(3): 233-235.
15. AM El-saghier; A Khodiyar, *Phosphorus, Sulfur and Silicon*, **2000**; 160: 105-119.
16. B Musicki; AM Periers; P Laurin; D Ferroud; Y Bendetti; S Lachaud; F Chatreaux; JL Haesslein; A Iltis; C Pierre; J Khider; N Tessot; P Airault; A Bonnefoy; P Vicat; M Klich, *Bioorg. Med. Chem. Lett*, **2000**; 10: 1695-1699.
17. J Azizian; AMohammadi; I Bidar; P Mirzaei, *Montash Chem*, **2008**; 139: 805-808.
18. VS Satyanarayan; P Sreevani; A Sivakumar, *Arkivoc*, **2008**; 17: 221-233.
19. MM Garazd; OV Muzychka; AI Voyk; IV Nagorichna; AS Ogorodniichuk, *Chemistry of Natural Compounds*, **2007**; 43(1): 19-23.
20. G Smitha; R Sanjeeva, *Synthetic Communications*, **2004**; 34(21): 3997-4003.
21. A Kotali; I Lafazanis; P Harris, *Synthetic Communications*, **2008**; 38: 3996-4006.
22. N Hamdi; C Lidrissi; M Saoud; AR Nievas; H Zarrouk, *Chemistry of Heterocyclic Compounds*, **2006**; 42(3): 320-325.

23. M Maheswara; V siddaiah; GL Damu; YK Rao; CV Rao, Journal of Molecular Catalysis A:Chemical, **2006**; 255: 49-52.
24. B Rrajitha; V Naveen; P someshwar; P Narsimha; Y Thirupathi, Arkivoc, **2006**; 12: 23-27.
25. M Zahradnik, The production and application of fluorescent brightening agents, John wiley & Sons, New York, **1992**.
26. ZA Sizova; AA Karasev; LL Lukatskaya; MI Rubtsov; AO Doroshenko, Theoretical And Experimental Chemistry, **2002**; 38(3): 168-172.
27. M Kováč; A Sabatié; L Floch, Arkivoc, **2001**; 6: 100-108.